Potentiating the effector functions of tumor-infiltrating FcγRIIIa-expressing immune cells may be a promising tailored strategy that could be matched to the appropriate TME conditions of patients with aggressive and treatment-resistant diseases. This evidence concerns the gene FCGR3A and neoplasm.